Evaluation of antifungal efficacy in an optimized animal model of Trichophyton mentagrophytes-dermatophytosis

Journal of Chemotherapy

Volumn 16, Issue 2, 2004, Pages 139-144

  Ghannoum, M A ^a,b   Hossain, M A ^a   Long, L ^a   Mohamed, S ^a   Reyes, G ^a   Mukherjee, P K ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antifungal agent; Dermatophytosis; Efficacy; Guinea pig; Model

Indexed keywords

ANTIDERMATOPHYTIC AGENT; ANTIFUNGAL AGENT; TERBINAFINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DERMATOMYCOSIS; DRUG EFFICACY; DRUG SCREENING; FUNGAL CELL; GUINEA PIG; INOCULATION; MALE; NONHUMAN; SCREENING; TRICHOPHYTON MENTAGROPHYTES;

EID: 2942548973     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.2.139     Document Type: Article

References (16)

1. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-259.
2. Hossain MA, Ghannoum MA New developments in chemotherapy for non-invasive fungal infections. Expert Opin Investig Drugs 2001; 10(8): 1501-1511.
3. Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998; 197: 162-166.
4. Norris HA, Elewski BE, Ghannoum MA. Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method. J Am Acad Dermatol 1999; 40: S9-13.
5. Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-344.
6. Treiber A, Pittermann W, Schuppe HC. Efficacy testing of antimycotic prophylactics in an animal model. Int J Hyg Environ Health 2001; 204 (4): 239-243.
7. Petranyi G, Leitner I, Mieth H. The "hair root invasion test", a semi-quantitative method for experimental evaluation of antimycotics in guinea-pigs. Sabouraudia 1982; 20: 101-108.
8. Bakos L, Brito AC, Castro LC et al. Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. Pediatr Infect Dis J 1997; 16: 545-548.
9. Drake LA, Shear NH, Ariette JP et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740-745.
10. Niewerth M, Korting HC. The use of systemic antimycotics in dermatotherapy. Eur J Dermatol 2000; 10: 155-160.
11. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14: 124-127.
12. Shear NH, Villars VV, Marsolais C. Terbinafine: an oral and topical antifungal agent. Clin Dermatol 1991; 9(4): 487-495.
13. Faergemann J, Zehender H, Denouel J, Millerioux L Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum comeum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993; 73: 305-309.
14. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-126.
15. Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000; 38(2): 155-159.
16. Ryder NS, Favre B. Antifungal activity and mechanism of action of. Rev Contemp Pharmacother 1997; 8: 275-287.